Literature DB >> 51409

Treatment of primary melanoma by intralesional vaccinia before excision.

J D Everall, C J O'Doherty, J Wand, P M Dowd.   

Abstract

The results of treatment of two groups of patients with primary melanoma are compared. 25 patients in group 1 were treated by wide local excision of the primary melanoma, and 23 in group 2 were treated by vaccination with live vaccinia virus 14 days before wide local excision. Vaccination exerts a favourable effect on the course of melanoma both in terms of survival and prolongation of the interval between treatment of the primary lesion and subsequent development of metastases.

Entities:  

Mesh:

Year:  1975        PMID: 51409     DOI: 10.1016/s0140-6736(75)90172-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

1.  Strategy in the management of melanoma.

Authors:  G Westbury
Journal:  Proc R Soc Med       Date:  1977-06

2.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

Review 3.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 4.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

5.  Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.

Authors:  P Hersey; A Edwards; A Coates; H Shaw; W McCarthy; G Milton
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 6.  Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.

Authors:  Dana Haddad
Journal:  Front Oncol       Date:  2017-05-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.